Photo of Nabihah Tayob,  PhD

Nabihah Tayob, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (857) 215-0006

Nabihah Tayob, PhD

Dana-Farber Cancer Institute


  • Faculty, Data Science, Dana-Farber Cancer Institute


Research Abstract

Dr. Tayob is co-Director of the Biostatistics and Computational Biology Core of the DF/HCC Breast SPORE and the co-Lead of the Biostatistics Core of the DF/HCC Ovarian SPORE. She is an active collaborator on research projects with investigators in the Susan F. Smith Center for Women's Cancers. She is also co-investigator on multiple NIH funded projects studying the early detection of hepatocellular carcinoma (HCC) and is the PI of an NIH funded project to develop statistical methods to improve early detection of HCC.

Dr. Tayob's current statistical methods research focuses on biomarker study design, evaluation and screening for early detection of cancer. Recent work includes developing statistical methods for evaluating a biomarker panel in a two-stage study with early termination for futility. Two-stage group sequential designs with early termination for futility are important and widely used in biomarker development studies because they allow us to conserve valuable sample specimens in the case of inadequate biomarker performance at interim analysis.

A key focus of her research is the development of statistical methods that use multiple longitudinal biomarkers when screening for early detection of HCC. Patients with cirrhosis are at high risk for HCC and recommended to undergo regular six-month surveillance. She has an NIH funded project where the goal is to develop statistical methods that use biomarker information collected at the current screening visit, as well as prior screening visits, to improve the likelihood of early detection of HCC. These types of screening algorithms could potentially be used in other high-risk cancer populations that undergo surveillance with biomarkers.

Dr. Tayob's doctoral research focused on developing statistical methods around the restricted mean survival, a clinically meaningful short-term outcome measure. Future research will explore the use of this measure in biomarker studies.


Powered by Harvard Catalyst
  • Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, Tolaney SM, Winer EP, Vallejo CT, Lin NU. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat 2021. PubMed
  • Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE, Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM, Shapiro GI, Tolaney SM. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 2021; 27:983-991. PubMed
  • Seah DS, Leone JP, Openshaw TH, Scott SM, Tayob N, Hu J, Lederman RI, Frank ES, Sohl JJ, Stadler ZK, Erick TK, Silverman SG, Peppercorn JM, Winer EP, Come SE, Lin NU. Perceptions of patients with early stage breast cancer toward research biopsies. Cancer 2020. PubMed
  • Tolaney SM, Lydon CA, Li T, Dai J, Standring A, Legor KA, Caparrotta CM, Schenker MP, Glazer DI, Tayob N, DuBois SG, Meyerhardt JA, Taplin ME, Johnson BE. The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. Journal of the National Cancer Institute 2020. PubMed
  • Tayob N, Corley DA, Christie I, Almers L, Rahal AK, Richardson P, White DL, Davila J, Kanwal F, El-Serag HB. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clin Gastroenterol Hepatol 2020. PubMed
  • Xia M, Murray S, Tayob N. Regression analysis of recurrent-event-free time from multiple follow-up windows. Stat Med 2020; 39:1-15. PubMed
  • Xia M, Murray S, Tayob N. Nonparametric group sequential methods for recurrent and terminal events from multiple follow-up windows. Stat Med 2020; 38:5657-5669. PubMed
  • Tayob N, Christie I, Richardson P, Feng Z, White DL, Davila J, Corley DA, Kanwal F, El-Serag HB. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol 2020; 17:1886-1893.e5. PubMed
  • Xia M, Murray S, Tayob N. Nonparametric group sequential methods for evaluating survival benefit from multiple short-term follow-up windows. Biometrics 2020; 75:494-505. PubMed
  • Tayob N, Stingo F, Do KA, Lok ASF, Feng Z. A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers. Biometrics 2019; 74:249-259. PubMed
  • Tayob N, Richardson P, White DL, Yu X, Davila JA, Kanwal F, Feng Z, El-Serag HB. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. 2020; 18:1. PubMed
  • Tayob N, Murray S. Statistical consequences of a successful lung allocation system - recovering information and reducing bias in models for urgency. Stat Med 2020; 36:2435-2451. PubMed
  • Tayob N, Lok AS, Do KA, Feng Z. Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. Clin Gastroenterol Hepatol 2019; 14:469-475.e2. PubMed
  • Tayob N, Murray S. Nonparametric restricted mean analysis across multiple follow-up intervals. Stat Probab Lett 2019; 109:152-158. PubMed
  • Tayob N, Do KA, Feng Z. Unbiased estimation of biomarker panel performance when combining training and testing data in a group sequential design. Biometrics 2018; 72:888-96. PubMed
  • Tayob N, Murray S. Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events. Biostatistics 2019; 16:73-83. PubMed
Member Summary Video